Evidence map›Paper›PMID 32753896›Full record

ReviewOncoTargets and therapy2020

MicroRNA-154: A Novel Candidate for Diagnosis and Therapy of Human Cancers.

Ali Nazarizadeh, Forogh Mohammadi, Fatemeh Alian, Parisa Faraji, Mitra Nourbakhsh, Shahin Alizadeh-Fanalou

Open access · goldAbstract readReview
In one paragraph

Review in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Diagnosis of cerebral malaria: Tools to reduceFrontiers in cellular and infection microbiology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ali Nazarizadeh *Department of Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.ORCID 0000-0003-0935-5142
Forogh Mohammadi *Department of Veterinary, Agriculture Faculty, Kermanshah Branch, Islamic Azad University, Kermanshah, Iran.
Fatemeh AlianInstitute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Parisa FarajiInstitute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Mitra NourbakhshDepartment of Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Shahin Alizadeh-FanalouDepartment of Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.ORCID 0000-0003-0448-7074
Iran University of Medical Sciences · IRUniversity of Tehran · IRIslamic Azad University of Kermanshah · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) are endogenous, non-coding, single-stranded, tiny RNAs with 21-23 nucleotides that regulate several biological functions through binding to target mRNAs and modulating gene expression at post-transcriptional levels. Recent studies have described crucial roles for miRNAs in pathophysiology of numerous human cancers. They can act as an oncogene and promote cancer or as a tumor suppressor and alleviate the disease. Recently discovered microRNA-154 (miR-154) has been proposed to be involved in multiple physiological and pathological processes including cancer. With this aspect, aberrant expression of miR-154 has been demonstrated in variety of human malignancies, suggesting an important role for miR-154 in tumorigenesis. To be specific, it is considered as a tumor suppressor miRNA and exerts its beneficial effects by targeting several genes. This review systematically summarizes the recent advances done on the role of miR-154 in different cancers and discusses its potential prognostic, diagnostic and therapeutic values.

Indexed as

cancermicroRNA-154target genetumor suppressor

Identifiers

PMID32753896
PMCPMC7354082
OpenAlexW3038982570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.